Signal sequence that induces protein secretion in intestinal microbiome
US-2024190925-A1 · Jun 13, 2024 · US
Immunoreactive glycoprotein GP19 of ehrlichia canis
US9605033B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9605033-B2 |
| Application number | US-201514729758-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 3, 2015 |
| Priority date | Aug 31, 2006 |
| Publication date | Mar 28, 2017 |
| Grant date | Mar 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention concerns gp19 immunoreactive compositions for E. canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. canis gp19 are disclosed.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of detecting an anti- E. canis antibody in an individual, comprising the step of assaying a biological sample from the individual for the presence of an antibody that immunologically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence that is 95% identical to SEQ ID NO: 13, wherein the polypeptide is 24 to 75 amino acids in length and the assaying comprises contacting the sample with the polypeptide. 2. The method of claim 1 , wherein the sample is assayed by contacting with the polypeptide comprising the amino acid sequence of SEQ ID NO: 13. 3. The method of claim 2 , wherein the polypeptide is bound to a solid support. 4. The method of claim 3 , wherein the solid support is a column matrix, a well of a microtiter plate, a dot blot membrane, or a Western blot membrane. 5. The method of claim 1 , wherein the sample is assayed by contacting with the polypeptide comprising the amino acid sequence that is at least 95% identical to SEQ ID NO: 13.
Assignees
Inventors
Classifications
from Richettsiales (o) · CPC title
Rickettsiales (O) · CPC title
Bacteria · CPC title
Veterinary vaccine · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9605033B2 cover?
- The present invention concerns gp19 immunoreactive compositions for E. canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. canis gp19 are disclosed.
- Who is the assignee on this patent?
- Res Dev Foundation
- What technology area does this patent fall under?
- Primary CPC classification C07K14/195. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).